

Titre	Étude multicentrique de phase III, à répartition aléatoire, contrôlée par placebo, visant à comparer l'efficacité de l'association MPDL3280A (anticorps anti-PD-L1) et nab-paclitaxel à celle de l'association placebo et nab-paclitaxel, chez des sujets atteints d'un cancer du sein triple négatif métastatique n'ayant jamais été traité auparavant.
Protocole ID	WO29522
ClinicalTrials.gov ID	NCT02425891
Type(s) de cancer	Sein
Phase	Phase III
Type étude	Traitement
Médicament	Atezolizumab (MPDL3280A) avec Nab Paclitaxel
Institution	CHU DE QUEBEC – UNIVERSITE LAVAL HOPITAL DU SAINT-SACREMENT 1050 Ch Ste-Foy, Québec, QC, G1S 4L8
Ville	Québec
Investigateur principal	Dre Louise Provencher
Coordonnateur	Isabelle Ouellet 418-682-7511 poste 4553
Statut	Fermé
But étude	This study is being conducted to determine the efficacy and safety in using Atezolizumab (MPDL3280A) in combination with nab-paclitaxel in treating patients with metastatic breast cancer. The safety of single-agent nab-paclitaxel has been determined in previous studies of patients with metastatic breast cancer, and preliminary data shows the use of MPDL3280A is safe to use in combination with chemotherapy.
Critères d'éligibilité	• Female > or = 18 years of age • Metastatic or locally advanced, histologically documented Triple-Negative Breast Cancer (TNBC) • No prior chemotherapy or targeted systemic therapy for inoperable locally advanced or metastatic TNBC • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 • Measurable disease • Adequate hematologic and end-organ function
Critères d'exclusion	• Known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases • Leptomeningeal disease • Pregnancy or lactation • History of autoimmune disease • Prior allogeneic stem cell or solid organ transplantation • Positive test for HIV • Active hepatitis B or hepatitis C